- In March 2025, Abbott announced successful U.S. trials for a next-generation bioabsorbable stent system with improved scaffold design and enhanced drug-elution profile
- In January 2025, Boston Scientific received FDA approval for its Synergy XD DES, an enhanced version with better flexibility and precision placement in tortuous vessel
- In October 2024, Medtronic launched a cobalt-chromium DES in Canada with a novel antiproliferative agent aimed at reducing late-stage thrombosis and improving long-term patency
